• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

    10/16/24 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Sales of $10.6 billion driven by strong underlying base business performance
    • Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices
    • Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data

    ABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2024.

    • Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.
    • Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales2.
    • Abbott now projects full-year diluted EPS on a GAAP basis of $3.34 to $3.40 and projects adjusted diluted EPS of $4.64 to $4.70, which represents an increase at the midpoint of the guidance range.
    • In October, Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares.
    • In August, Abbott announced a unique global partnership with Medtronic to collaborate on connecting Abbott's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices.
    • In September, Abbott announced the U.S. launch of Lingo™, the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness.
    • In September, Abbott announced a partnership with the Big Ten Conference® to conduct a nationwide blood donation competition to help increase the U.S. blood supply.
    • In September, Abbott completed enrollment ahead of schedule in its VOLT-AF IDE trial, which is designed to evaluate the Volt™ Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).

    "Our results this quarter demonstrate the strength of our diversified business model," said Robert B. Ford, chairman and chief executive officer, Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year."

    THIRD-QUARTER BUSINESS OVERVIEW

    Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.

    Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

    Third Quarter 2024 Results (3Q24)



    Sales 3Q24 ($ in millions)

    Total Company



    Nutrition



    Diagnostics



    Established

    Pharmaceuticals



    Medical Devices

    U.S.

    4,202



    950



    1,032



    —



    2,216

    International

    6,433



    1,116



    1,380



    1,406



    2,531

    Total reported

    10,635



    2,066



    2,412



    1,406



    4,747





















    % Change vs. 3Q23



















    U.S.

    10.1



    10.4



    1.8



    n/a



    14.2

    International

    1.7



    (7.9)



    (3.8)



    2.7



    9.6

    Total reported

    4.9



    (0.3)



    (1.5)



    2.7



    11.7

    Impact of foreign exchange

    (2.5)



    (3.1)



    (2.9)



    (4.3)



    (1.6)

    Impact of business exit*

    (0.2)



    (0.6)



    —



    —



    —

    Organic

    7.6



    3.4



    1.4



    7.0



    13.3

    Impact of COVID-19 testing sales (3)

    (0.6)



    —



    (1.9)



    —



    —

    Organic (excluding COVID-19 tests)

    8.2



    3.4



    3.3



    7.0



    13.3





















        U.S.

    11.0



    11.9



    2.4



    n/a



    14.2

        International

    6.5



    (2.6)



    3.8



    7.0



    12.5

     

    First Nine Months 2024 Results (9M24)



    Sales 9M24 ($ in millions)

    Total Company



    Nutrition



    Diagnostics



    Established

    Pharmaceuticals



    Medical Devices

    U.S.

    11,982



    2,761



    2,775



    —



    6,435

    International

    18,994



    3,523



    4,046



    3,926



    7,499

    Total reported

    30,976



    6,284



    6,821



    3,926



    13,934





















    % Change vs. 9M23



















    U.S.

    4.2



    8.1



    (16.2)



    n/a



    14.3

    International

    3.4



    (1.1)



    (2.4)



    2.1



    10.1

    Total reported

    3.7



    2.7



    (8.5)



    2.1



    12.0

    Impact of foreign exchange

    (3.0)



    (3.1)



    (2.9)



    (7.3)



    (1.6)

    Impact of business exit and acquisition*

    0.1



    (0.4)



    —



    —



    0.4

    Organic

    6.6



    6.2



    (5.6)



    9.4



    13.2

    Impact of COVID-19 testing sales (3)

    (2.8)



    —



    (10.4)



    —



    —

    Organic (excluding COVID-19 tests)

    9.4



    6.2



    4.8



    9.4



    13.2





















        U.S.

    10.0



    9.0



    3.0



    n/a



    13.3

        International

    9.0



    4.2



    5.9



    9.4



    13.1

     

    Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

    *Quarter to date Sept. 30, 2024, reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.  Year to date Sept. 30, 2024, reflects the impact of discontinuing the ZonePerfect  product line in the Nutrition business in March 2024 and the acquisition of CSI on April 27, 2023. Organic sales growth excludes the impact of the acquired business from January through April 2024.

     

    Nutrition



    Third Quarter 2024 Results (3Q24)



    Sales 3Q24 ($ in millions)

    Total



    Pediatric



    Adult

    U.S.

    950



    568



    382

    International

    1,116



    387



    729

    Total reported

    2,066



    955



    1,111













    % Change vs. 3Q23











    U.S.

    10.4



    12.2



    7.9

    International

    (7.9)



    (21.6)



    1.5

    Total reported

    (0.3)



    (4.5)



    3.6

    Impact of foreign exchange

    (3.1)



    (1.8)



    (4.4)

    Impact of business exit*

    (0.6)



    —



    (1.1)

    Organic

    3.4



    (2.7)



    9.1













        U.S.

    11.9



    12.2



    11.5

        International

    (2.6)



    (18.0)



    8.0

     

    Worldwide Nutrition sales decreased 0.3 percent on a reported basis and increased 3.4 percent on an organic basis in the third quarter, led by growth in Adult Nutrition.

    In Adult Nutrition, global sales increased 3.6 percent on a reported basis and 9.1 percent on an organic basis, which was led by growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand. 

    First Nine Months 2024 Results (9M24)



    Sales 9M24 ($ in millions)

    Total



    Pediatric



    Adult

    U.S.

    2,761



    1,646



    1,115

    International

    3,523



    1,377



    2,146

    Total reported

    6,284



    3,023



    3,261













    % Change vs. 9M23











    U.S.

    8.1



    11.8



    3.2

    International

    (1.1)



    (6.8)



    2.8

    Total reported

    2.7



    2.5



    3.0

    Impact of foreign exchange

    (3.1)



    (1.6)



    (4.4)

    Impact of business exit*

    (0.4)



    —



    (0.7)

    Organic

    6.2



    4.1



    8.1













        U.S.

    9.0



    11.8



    5.0

        International

    4.2



    (3.6)



    9.7

    *Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.

     

    Diagnostics



    Third Quarter 2024 Results (3Q24)



    Sales 3Q24 ($ in millions)

    Total



    Core Laboratory



    Molecular



    Point of Care



    Rapid

    Diagnostics

    U.S.

    1,032



    332



    37



    103



    560

    International

    1,380



    982



    91



    43



    264

    Total reported

    2,412



    1,314



    128



    146



    824





















    % Change vs. 3Q23



















    U.S.

    1.8



    4.5



    (2.8)



    6.0



    (0.2)

    International

    (3.8)



    (1.5)



    (3.9)



    0.7



    (12.2)

    Total reported

    (1.5)



    —



    (3.6)



    4.4



    (4.4)

    Impact of foreign exchange

    (2.9)



    (4.3)



    (1.5)



    (0.2)



    (1.4)

    Organic

    1.4



    4.3



    (2.1)



    4.6



    (3.0)

    Impact of COVID-19 testing sales (3)

    (1.9)



    (0.2)



    (3.9)



    —



    (3.4)

    Organic (excluding COVID-19 tests)

    3.3



    4.5



    1.8



    4.6



    0.4





















        U.S.

    2.4



    4.8



    4.5



    6.0



    (1.0)

        International

    3.8



    4.4



    0.8



    1.3



    2.8

     

    As expected, Diagnostics sales growth in the third quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $265 million in the third quarter of 2024 compared to $305 million in the third quarter of the prior year.

    Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 3.3 percent on an organic basis.

    Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales grew 0.1 percent on a reported basis and increased 4.5 percent on an organic basis, led by continued adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.  

    First Nine Months 2024 Results (9M24)



    Sales 9M24 ($ in millions)

    Total



    Core Laboratory



    Molecular



    Point of Care



    Rapid

    Diagnostics

    U.S.

    2,775



    969



    112



    308



    1,386

    International

    4,046



    2,879



    272



    133



    762

    Total reported

    6,821



    3,848



    384



    441



    2,148





















    % Change vs. 9M23



















    U.S.

    (16.2)



    5.6



    (12.3)



    6.6



    (29.8)

    International

    (2.4)



    0.3



    (7.2)



    4.8



    (10.6)

    Total reported

    (8.5)



    1.5



    (8.7)



    6.0



    (24.0)

    Impact of foreign exchange

    (2.9)



    (4.8)



    (0.8)



    (0.1)



    (1.1)

    Organic

    (5.6)



    6.3



    (7.9)



    6.1



    (22.9)

    Impact of COVID-19 testing sales (3)

    (10.4)



    (0.2)



    (6.3)



    —



    (25.0)

    Organic (excluding COVID-19 tests)

    4.8



    6.5



    (1.6)



    6.1



    2.1





















        U.S.

    3.0



    5.9



    (3.3)



    6.6



    (0.1)

        International

    5.9



    6.7



    (0.9)



    5.1



    5.7

     

    Established Pharmaceuticals



    Third Quarter 2024 Results (3Q24)



    Sales 3Q24 ($ in millions)

    Total



    Key Emerging

    Markets



    Other

    U.S.

    —



    —



    —

    International

    1,406



    994



    412

    Total reported

    1,406



    994



    412













    % Change vs. 3Q23











    U.S.

    n/a



    n/a



    n/a

    International

    2.7



    0.7



    8.1

    Total reported

    2.7



    0.7



    8.1

    Impact of foreign exchange

    (4.3)



    (4.7)



    (3.1)

    Organic

    7.0



    5.4



    11.2













        U.S.

    n/a



    n/a



    n/a

        International

    7.0



    5.4



    11.2

     

    Established Pharmaceuticals sales increased 2.7 percent on a reported basis and 7.0 percent on an organic basis in the third quarter.

    Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.7 percent on a reported basis and increased 5.4 percent on an organic basis, led by growth in several geographies and therapeutic areas, including gastroenterology, cardiometabolic, and central nervous system/pain management. 

    First Nine Months 2024 Results (9M24)



    Sales 9M24 ($ in millions)

    Total



    Key Emerging

    Markets



    Other

    U.S.

    —



    —



    —

    International

    3,926



    2,910



    1,016

    Total reported

    3,926



    2,910



    1,016













    % Change vs. 9M23











    U.S.

    n/a



    n/a



    n/a

    International

    2.1



    0.7



    6.4

    Total reported

    2.1



    0.7



    6.4

    Impact of foreign exchange

    (7.3)



    (9.0)



    (2.2)

    Organic

    9.4



    9.7



    8.6













        U.S.

    n/a



    n/a



    n/a

        International

    9.4



    9.7



    8.6

     

    Medical Devices



    Third Quarter 2024 Results (3Q24)



    Sales 3Q24 ($ in millions)

    Total



    Rhythm

    Management



    Electro-

    physiology



    Heart

    Failure



    Vascular



    Structural

    Heart



    Neuro-

    modulation



    Diabetes

    Care

    U.S.

    2,216



    288



    285



    252



    258



    270



    190



    673

    International

    2,531



    309



    325



    70



    441



    288



    46



    1,052

    Total reported

    4,747



    597



    610



    322



    699



    558



    236



    1,725

































    % Change vs. 3Q23































    U.S.

    14.2



    6.0



    15.8



    16.7



    2.8



    21.1



    0.8



    23.6

    International

    9.6



    5.7



    9.2



    5.2



    4.5



    9.2



    17.8



    13.3

    Total reported

    11.7



    5.9



    12.2



    14.0



    3.9



    14.6



    3.8



    17.1

    Impact of foreign exchange

    (1.6)



    (1.1)



    (2.1)



    (0.4)



    (1.0)



    (1.9)



    (1.4)



    (2.0)

    Organic

    13.3



    7.0



    14.3



    14.4



    4.9



    16.5



    5.2



    19.1

































        U.S.

    14.2



    6.0



    15.8



    16.7



    2.8



    21.1



    0.8



    23.6

        International

    12.5



    7.9



    13.0



    6.6



    6.2



    12.6



    25.7



    16.5

     

    Worldwide Medical Devices sales increased 11.7 percent on a reported basis and 13.3 percent on an organic basis in the third quarter, including double-digit organic growth in both the U.S. and internationally.

    Sales growth was led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip®, Amplatzer® Amulet®, and AVEIR®.

    In Electrophysiology, sales grew 12.2 percent on a reported basis and 14.3 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products.

    In Diabetes Care, sales of continuous glucose monitors exceeded $1.6 billion and grew 19.1 percent on a reported basis and 20.7 percent on an organic basis. 

    First Nine Months 2024 Results (9M24)



    Sales 9M24 ($ in millions)

    Total



    Rhythm

    Management



    Electro-

    physiology



    Heart

    Failure



    Vascular



    Structural

    Heart



    Neuro-

    modulation



    Diabetes

    Care

    U.S.

    6,435



    851



    841



    733



    787



    761



    563



    1,899

    International

    7,499



    915



    983



    215



    1,325



    876



    142



    3,043

    Total reported

    13,934



    1,766



    1,824



    948



    2,112



    1,637



    705



    4,942

































    % Change vs. 9M23































    U.S.

    14.3



    6.4



    15.3



    11.0



    7.4



    16.7



    6.5



    24.3

    International

    10.1



    4.8



    12.6



    8.2



    4.2



    10.3



    16.5



    13.5

    Total reported

    12.0



    5.6



    13.8



    10.4



    5.4



    13.2



    8.4



    17.4

    Impact of foreign exchange

    (1.6)



    (1.2)



    (2.6)



    (0.1)



    (1.3)



    (1.9)



    (1.5)



    (1.9)

    Impact of acquisition*

    0.4



    —



    —



    —



    2.8



    —



    —



    —

    Organic

    13.2



    6.8



    16.4



    10.5



    3.9



    15.1



    9.9



    19.3

































        U.S.

    13.3



    6.4



    15.3



    11.0



    0.1



    16.7



    6.5



    24.3

        International

    13.1



    7.1



    17.4



    8.9



    6.0



    13.7



    24.6



    16.5



    *Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.

     

    ABBOTT'S EARNINGS-PER-SHARE GUIDANCE

    Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.34 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.64 to $4.70 for the full-year 2024.

    Abbott projects fourth-quarter 2024 diluted earnings per share under GAAP of $0.96 to $1.02. Abbott forecasts specified items for the fourth-quarter 2024 of $0.35 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.31 to $1.37 for the fourth quarter 2024.

    ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND

    On Sept. 19, 2024, the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024.

    Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

    — Private Securities Litigation Reform Act of 1995 —

    A Caution Concerning Forward-Looking Statements

    Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    1

    In the third quarter of 2024, total worldwide sales were $10.635 billion and COVID-19 testing-related sales were $265 million. In the third quarter of 2023, total worldwide sales were $10.143 billion and COVID-19 testing-related sales were $305 million.





    2

    Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.





    3

    Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below:

     



    Sales 3Q24





    COVID Tests Sales 3Q24

    ($ in millions)

    U.S.



    Int'l



    Total





    U.S.



    Int'l



    Total

    Total Diagnostics

    1,032



    1,380



    2,412





    206



    59



    265

    Core Laboratory

    332



    982



    1,314





    1



    2



    3

    Molecular

    37



    91



    128





    2



    1



    3

    Rapid Diagnostics

    560



    264



    824





    203



    56



    259





























    Sales 3Q23





    COVID Tests Sales 3Q23

    ($ in millions)

    U.S.



    Int'l



    Total





    U.S.



    Int'l



    Total

    Total Diagnostics

    1,013



    1,436



    2,449





    207



    98



    305

    Core Laboratory

    317



    997



    1,314





    2



    3



    5

    Molecular

    38



    95



    133





    5



    3



    8

    Rapid Diagnostics

    561



    301



    862





    200



    92



    292





























    Sales 9M24





    COVID Tests Sales 9M24

    ($ in millions)

    U.S.



    Int'l



    Total





    U.S.



    Int'l



    Total

    Total Diagnostics

    2,775



    4,046



    6,821





    428



    143



    571

    Core Laboratory

    969



    2,879



    3,848





    3



    5



    8

    Molecular

    112



    272



    384





    7



    3



    10

    Rapid Diagnostics

    1,386



    762



    2,148





    418



    135



    553





























    Sales 9M23





    COVID Tests Sales 9M23

    ($ in millions)

    U.S.



    Int'l



    Total





    U.S.



    Int'l



    Total

    Total Diagnostics

    3,309



    4,145



    7,454





    1,031



    267



    1,298

    Core Laboratory

    917



    2,872



    3,789





    6



    10



    16

    Molecular

    128



    293



    421





    19



    17



    36

    Rapid Diagnostics

    1,975



    853



    2,828





    1,006



    240



    1,246

     

    Abbott Laboratories and Subsidiaries

    Condensed Consolidated Statement of Earnings

    Third Quarter Ended September 30, 2024 and 2023

    (in millions, except per share data)

    (unaudited)









    3Q24



    3Q23



    % Change



    Net Sales

    $10,635



    $10,143



    4.9

















    Cost of products sold, excluding amortization expense

    4,698



    4,605



    2.0



    Amortization of intangible assets

    470



    496



    (5.1)



    Research and development

    713



    672



    6.1



    Selling, general, and administrative

    2,895



    2,723



    6.3



    Total Operating Cost and Expenses

    8,776



    8,496



    3.3

















    Operating Earnings

    1,859



    1,647



    12.8

















    Interest expense, net

    51



    69



    (26.0)



    Net foreign exchange (gain) loss

    (11)



    (10)



    n/m



    Other (income) expense, net

    (121)



    (83)



    n/m



    Earnings before taxes

    1,940



    1,671



    16.1



    Taxes on earnings

    294



    235



    25.6

















    Net Earnings

    $1,646



    $1,436



    14.6

















    Net Earnings excluding Specified Items, as described below

    $2,119



    $2,000



    5.9

    1)















    Diluted Earnings per Common Share

    $0.94



    $0.82



    14.6

















    Diluted Earnings per Common Share,

    excluding Specified Items, as described below

    $1.21



    $1.14



    6.1

    1)















    Average Number of Common Shares Outstanding

    Plus Dilutive Common Stock Options

    1,748



    1,748







     

    NOTES:

    See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

    n/m = Percent change is not meaningful.

    See footnotes on the following section.





    1)

    2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $473 million, or $0.27 per share, for intangible amortization, charges related to intangible impairment, expenses associated with acquisitions and a divestiture, and other net expenses.







    2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $564 million, or $0.32 per share, for intangible amortization, charges related to the impairment of R&D intangible assets, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses.

     

    Abbott Laboratories and Subsidiaries

    Condensed Consolidated Statement of Earnings

    Nine Months Ended September 30, 2024 and 2023

    (in millions, except per share data)

    (unaudited)









    9M24



    9M23



    % Change



    Net Sales

    $30,976



    $29,868



    3.7

















    Cost of products sold, excluding amortization expense

    13,764



    13,419



    2.6



    Amortization of intangible assets

    1,413



    1,485



    (4.9)



    Research and development

    2,095



    2,041



    2.6



    Selling, general, and administrative

    8,790



    8,225



    6.9



    Total Operating Cost and Expenses

    26,062



    25,170



    3.5

















    Operating Earnings

    4,914



    4,698



    4.6

















    Interest expense, net

    170



    182



    (6.4)



    Net foreign exchange (gain) loss

    (17)



    17



    n/m



    Other (income) expense, net

    (222)



    (370)



    n/m



    Earnings before taxes

    4,983



    4,869



    2.3



    Taxes on earnings

    810



    740



    9.6

    1)















    Net Earnings

    $4,173



    $4,129



    1.0

















    Net Earnings excluding Specified Items, as described below

    $5,851



    $5,708



    2.5

    2)















    Diluted Earnings per Common Share

    $2.38



    $2.35



    1.3

















    Diluted Earnings per Common Share,

    excluding Specified Items, as described below

    $3.33



    $3.25



    2.5

    2)















    Average Number of Common Shares Outstanding

    Plus Dilutive Common Stock Options

    1,749



    1,750







     

    NOTES:

    See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

    n/m = Percent change is not meaningful.

    See footnotes on the following section.



    1)

    2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.







    2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years.





    2)

    2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.678 billion, or $0.95 per share, for intangible amortization, charges related to intangible impairment, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.







    2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.579 billion, or $0.90 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

     

    Abbott Laboratories and Subsidiaries

    Non-GAAP Reconciliation of Financial Information

    Third Quarter Ended September 30, 2024 and 2023

    (in millions, except per share data)

    (unaudited)





    3Q24



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $            470



    $          (470)



    $              —

    Gross Margin

    5,467



    516



    5,983

    R&D

    713



    (19)



    694

    SG&A

    2,895



    (5)



    2,890

    Other (income) expense, net

    (121)



    (12)



    (133)

    Earnings before taxes

    1,940



    552



    2,492

    Taxes on Earnings

    294



    79



    373

    Net Earnings

    1,646



    473



    2,119

    Diluted Earnings per Share

    $           0.94



    $           0.27



    $           1.21

     

    Specified items reflect intangible amortization expense of $470 million and other net expenses of $82 million associated with charges related to intangible impairment, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.



    3Q23



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $            496



    $          (496)



    $              —

    Gross Margin

    5,042



    542



    5,584

    R&D

    672



    (46)



    626

    SG&A

    2,723



    (43)



    2,680

    Other (income) expense, net

    (83)



    (23)



    (106)

    Earnings before taxes

    1,671



    654



    2,325

    Taxes on Earnings

    235



    90



    325

    Net Earnings

    1,436



    564



    2,000

    Diluted Earnings per Share

    $           0.82



    $           0.32



    $           1.14

     

    Specified items reflect intangible amortization expense of $496 million and other net expenses of $158 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

    Abbott Laboratories and Subsidiaries

    Non-GAAP Reconciliation of Financial Information

    Nine Months Ended September 30, 2024 and 2023

    (in millions, except per share data)

    (unaudited)





    9M24



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $         1,413



    $       (1,413)



    $              —

    Gross Margin

    15,799



    1,540



    17,339

    R&D

    2,095



    (81)



    2,014

    SG&A

    8,790



    (96)



    8,694

    Other (income) expense, net

    (222)



    (183)



    (405)

    Earnings before taxes

    4,983



    1,900



    6,883

    Taxes on Earnings

    810



    222



    1,032

    Net Earnings

    4,173



    1,678



    5,851

    Diluted Earnings per Share

    $           2.38



    $           0.95



    $           3.33

     

    Specified items reflect intangible amortization expense of $1.413 billion and other net expenses of $487 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.



    9M23



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $         1,485



    $       (1,485)



    $              —

    Gross Margin

    14,964



    1,591



    16,555

    R&D

    2,041



    (144)



    1,897

    SG&A

    8,225



    (67)



    8,158

    Other (income) expense, net

    (370)



    34



    (336)

    Earnings before taxes

    4,869



    1,768



    6,637

    Taxes on Earnings

    740



    189



    929

    Net Earnings

    4,129



    1,579



    5,708

    Diluted Earnings per Share

    $           2.35



    $           0.90



    $           3.25

     

    Specified items reflect intangible amortization expense of $1.485 billion and other net expenses of $283 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

    A reconciliation of the third-quarter tax rates for 2024 and 2023 is shown below:



    3Q24



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         1,940



    $            294



    15.2 %



    Specified items

    552



    79







    Excluding specified items

    $         2,492



    $            373



    15.0 %



















    3Q23



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         1,671



    $            235



    14.0 %



    Specified items

    654



    90







    Excluding specified items

    $         2,325



    $            325



    14.0 %



     

    A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below: 



    9M24



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         4,983



    $            810



    16.3 %

    1)

    Specified items

    1,900



    222







    Excluding specified items

    $         6,883



    $         1,032



    15.0 %



















    9M23



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         4,869



    $            740



    15.2 %

    2)

    Specified items

    1,768



    189







    Excluding specified items

    $         6,637



    $            929



    14.0 %







    1)

    2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.





    2)

    2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years.

     

    Abbott Laboratories and Subsidiaries

    Non-GAAP Revenue Reconciliation

    Third Quarter and Nine Months Ended September 30, 2024 and 2023

    ($ in millions)

    (unaudited)







    3Q24



    3Q23



    % Change vs. 3Q23

























    Non-GAAP





    Abbott

    Reported

    Impact from

    business exit (b)

    Adjusted

    Revenue



    Abbott

    Reported

    Impact from

    business exit (b)

    Adjusted

    Revenue



    Reported



    Adjusted

    Organic

    Total Company



    10,635

    (5)

    10,630



    10,143

    (17)

    10,126



    4.9



    5.1

    7.6

    U.S.



    4,202

    (5)

    4,197



    3,817

    (17)

    3,800



    10.1



    10.4

    10.4

    Intl



    6,433

    —

    6,433



    6,326

    —

    6,326



    1.7



    1.7

    5.8





























    Total Nutrition



    2,066

    (5)

    2,061



    2,073

    (17)

    2,056



    (0.3)



    0.3

    3.4

    U.S.



    950

    (5)

    945



    860

    (17)

    843



    10.4



    11.9

    11.9

    Intl



    1,116

    —

    1,116



    1,213

    —

    1,213



    (7.9)



    (7.9)

    (2.6)





























    Adult Nutrition



    1,111

    (5)

    1,106



    1,072

    (17)

    1,055



    3.6



    4.7

    9.1

    U.S.



    382

    (5)

    377



    354

    (17)

    337



    7.9



    11.5

    11.5

    Intl



    729

    —

    729



    718

    —

    718



    1.5



    1.5

    8.0





























    Total Medical Devices



    4,747

    —

    4,747



    4,249

    —

    4,249



    11.7



    11.7

    13.3

    U.S.



    2,216

    —

    2,216



    1,940

    —

    1,940



    14.2



    14.2

    14.2

    Intl



    2,531

    —

    2,531



    2,309

    —

    2,309



    9.6



    9.6

    12.5





























    Vascular



    699

    —

    699



    672

    —

    672



    3.9



    3.9

    4.9

    U.S.



    258

    —

    258



    251

    —

    251



    2.8



    2.8

    2.8

    Intl



    441

    —

    441



    421

    —

    421



    4.5



    4.5

    6.2

     



    9M24



    9M23



    % Change vs. 9M23























    Non-GAAP



    Abbott

    Reported

    Impact of

    acquisition (a)

    Impact from

    business

    exit (b)

    Adjusted

    Revenue



    Abbott

    Reported

    Impact from

    business

    exit (b)

    Adjusted

    Revenue



    Reported

    Adjusted

    Organic

    Total Company

    30,976

    (57)

    (13)

    30,906



    29,868

    (32)

    29,836



    3.7

    3.6

    6.6

    U.S.

    11,982

    (53)

    (13)

    11,916



    11,503

    (32)

    11,471



    4.2

    3.9

    3.9

    Intl

    18,994

    (4)

    —

    18,990



    18,365

    —

    18,365



    3.4

    3.4

    8.3



























    Total Nutrition

    6,284

    —

    (13)

    6,271



    6,116

    (32)

    6,084



    2.7

    3.1

    6.2

    U.S.

    2,761

    —

    (13)

    2,748



    2,553

    (32)

    2,521



    8.1

    9.0

    9.0

    Intl

    3,523

    —

    —

    3,523



    3,563

    —

    3,563



    (1.1)

    (1.1)

    4.2



























    Adult Nutrition

    3,261

    —

    (13)

    3,248



    3,167

    (32)

    3,135



    3.0

    3.7

    8.1

    U.S.

    1,115

    —

    (13)

    1,102



    1,081

    (32)

    1,049



    3.2

    5.0

    5.0

    Intl

    2,146

    —

    —

    2,146



    2,086

    —

    2,086



    2.8

    2.8

    9.7



























    Total Medical Devices

    13,934

    (57)

    —

    13,877



    12,444

    —

    12,444



    12.0

    11.6

    13.2

    U.S.

    6,435

    (53)

    —

    6,382



    5,631

    —

    5,631



    14.3

    13.3

    13.3

    Intl

    7,499

    (4)

    —

    7,495



    6,813

    —

    6,813



    10.1

    10.0

    13.1



























    Vascular

    2,112

    (57)

    —

    2,055



    2,004

    —

    2,004



    5.4

    2.6

    3.9

    U.S.

    787

    (53)

    —

    734



    733

    —

    733



    7.4

    0.1

    0.1

    Intl

    1,325

    (4)

    —

    1,321



    1,271

    —

    1,271



    4.2

    3.9

    6.0





    (a)

    Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.

    (b)

    Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    Third Quarter Ended September 30, 2024

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                  —



    $                    2



    $                470



    $                  44



    $                516

    R&D

    —



    —



    —



    (19)



    (19)

    SG&A

    (7)



    2



    —



    —



    (5)

    Other (income) expense, net

    (5)



    —



    —



    (7)



    (12)

    Earnings before taxes

    $                  12



    $                  —



    $                470



    $                  70



    552

    Taxes on Earnings (d)

















    79

    Net Earnings

















    $                473

    Diluted Earnings per Share

















    $               0.27





    The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."





    a)

    Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment and intangible asset impairment charges.





    d)

    Reflects the net tax benefit associated with the specified items.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    Third Quarter Ended September 30, 2023

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                    3



    $                  19



    $                496



    $                  24



    $                542

    R&D

    (1)



    (13)



    —



    (32)



    (46)

    SG&A

    (22)



    (22)



    —



    1



    (43)

    Other (income) expense, net

    5



    —



    —



    (28)



    (23)

    Earnings before taxes

    $                  21



    $                  54



    $                496



    $                  83



    654

    Taxes on Earnings (d)

















    90

    Net Earnings

















    $                564

    Diluted Earnings per Share

















    $               0.32





    The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."



    a)

    Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as legal and other costs related to business acquisitions.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments.





    d)

    Reflects the net tax benefit associated with the specified items.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    Nine Months Ended September 30, 2024

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                    2



    $                  76



    $             1,413



    $                  49



    $             1,540

    R&D

    (4)



    (1)



    —



    (76)



    (81)

    SG&A

    (32)



    (17)



    —



    (47)



    (96)

    Other (income) expense, net

    (140)



    —



    —



    (43)



    (183)

    Earnings before taxes

    $                178



    $                  94



    $             1,413



    $                215



    1,900

    Taxes on Earnings (d)

















    222

    Net Earnings

















    $             1,678

    Diluted Earnings per Share

















    $               0.95





    The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."





    a)

    Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.





    d)

    Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    Nine Months Ended September 30, 2023

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                  15



    $                  51



    $             1,485



    $                  40



    $             1,591

    R&D

    (13)



    (5)



    —



    (126)



    (144)

    SG&A

    (43)



    (28)



    —



    4



    (67)

    Other (income) expense, net

    46



    —



    —



    (12)



    34

    Earnings before taxes

    $                  25



    $                  84



    $             1,485



    $                174



    1,768

    Taxes on Earnings (d)

















    189

    Net Earnings

















    $             1,579

    Diluted Earnings per Share

















    $               0.90





    The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."



    a)

    Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments.





    d)

    Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.

     

    Cision View original content:https://www.prnewswire.com/news-releases/abbott-reports-third-quarter-2024-results-and-raises-midpoint-of-full-year-eps-guidance-range-302277755.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    4/20/2023$107.00 → $103.00Underperform
    Wolfe Research
    More analyst ratings

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

      The test, run on Abbott's portable i-STAT® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutesThe test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025ABBOTT PARK, Ill., and IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and MotoAmerica, the premier motorcycle road racing series in North America, announced today that MotoAmerica is the first professional sports organization worldwide to use Abbott's groundbreaking blood test to help assess suspe

      5/1/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Financials

    Live finance-specific insights

    See more
    • Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

      First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

      4/16/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for First-Quarter Earnings

      ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi

      3/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/23 10:54:50 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/22 3:15:56 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Labs downgraded by Edward Jones

      Edward Jones downgraded Abbott Labs from Buy to Hold

      7/30/24 6:16:11 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $ABT
    SEC Filings

    See more
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abbott Laboratories

      10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

      4/30/25 4:14:32 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      4/28/25 4:10:13 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care